Infinity Reports Phase 1 Data of IPI-145 at Sixth Annual T-Cell Lymphoma Forum Wall Street Journal An investigator-sponsored Phase 1b, open-label study of IPI-145 in patients with B-cell NHL, CLL and T-cell lymphoma in combination with rituximab (a monoclonal antibody therapy), bendamustine (a chemotherapy) or both rituximab and bendamustine is ... |
